Unlike HER2-positive and triple-negative breast cancer, NCT or NET for HR-positive, HER2-negative breast cancer only achieves a pCR rate of ≤10% (Cortazar et al., 2014). This evidence concerns the gene ERBB2 and breast carcinoma.